Latest Market Entry News

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

Botanix Pharmaceuticals’ ECCLOCK® gel, a treatment for excessive sweating, has secured regulatory approval in South Korea, paving the way for a commercial launch in early 2026.

Locksley Resources has listed on the Frankfurt Stock Exchange, boosting its profile in Europe while advancing its Mojave critical minerals project in the U.S. The company is also exploring multiple pathways to enter U.S. capital markets and has secured key government registrations.

Pure Hydrogen Corporation has signed a Letter of Intent with California's GTS Group to supply hydrogen-powered heavy vehicles, marking a strategic push into the North American market.

Halo Technologies Holdings Ltd has announced a renounceable pro rata rights issue aiming to raise up to $11 million at $0.024 per share, partially underwritten by Lodge Corporate Pty Ltd. The capital raise will support the company’s UK market entry, local growth, and ongoing software development.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

Imricor Medical Systems has taken a significant step toward U.S. market entry by submitting its Vision-MR Diagnostic Catheter for FDA 510(k) approval, complementing its recent NorthStar system filing. These moves aim to establish a fully integrated MRI-guided cardiac ablation platform.

Range International Limited reported a significantly reduced half-year loss alongside a 63% revenue increase, driven by strong pallet sales and resolution of Indonesian tax disputes. The company is now positioning for growth with factory relocations and new market entries.

Firebrick Pharma reported a substantial increase in Nasodine Nasal Spray revenues in FY25, alongside a widening net loss driven by reduced R&D incentives and increased marketing investments. The company is advancing its international rollout with new licensing deals and board appointments.

Bioxyne Limited delivered a record FY25 with $30.4 million revenue, driven by Australian market growth and new European contracts. The company projects revenue up to $75 million in FY26, fueled by expanded production and international market entries.

4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.

EPX Limited reported a robust 17% increase in revenue for FY2025, driven by a surge in recurring revenue and strategic expansion into industrial sectors following the Coda Cloud acquisition.